Responders to renal cell carcinoma agent show longer survival rates

Responders to the multi-targeted receptor tyrosine kinase inhibitor sunitinib (Sutent) have significantly longer progression-free survival and overall survival than non-responders, according to an analysis of 1,059 patients who participated in six clinical trials of sunitinib as first- or second-line therapy of metastatic renal cell carcinoma.

Related Videos
Matthew J. Ziegelmann, MD, answers a question during a Zoom video interview
Dr. Smita De in an interview with Urology Times
Doctor receiving patient in office | Image Credit © Africa Studio - stock.adobe.com
Alisa J. Stephens-Shields, PhD, answers a question during a Zoom video interview
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Dr. David Sheyn in an interview with Urology Times
Avinash Maganty, MD, answers a question during a Zoom video interview
blur image background of corridor in hospital or clinic image | Image Credit:  © whyframeshot - stock.adobe.com
Rachel Pope, MD, MPH, answers a question during a Zoom interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.